BPC-157 Effect on AST: What the Research Shows

What AST Measures and Why It Matters for Peptide Users

Aspartate aminotransferase (AST) is an intracellular enzyme found in hepatocytes, cardiomyocytes, skeletal muscle, and renal tubular cells. When those cells are damaged, AST leaks into the bloodstream and serum levels rise. A normal reference range for most labs falls between 10 and 40 IU/L [1].

AST Is Not Liver-Specific

Unlike ALT, which concentrates heavily in hepatocytes, AST distributes across multiple tissues. An isolated AST rise after a hard training session may reflect muscle breakdown rather than liver pathology. The AST:ALT ratio (also called the De Ritis ratio) helps clinicians differentiate sources: a ratio above 2.0 suggests alcoholic hepatitis, while a ratio below 1.0 more often points to non-alcoholic fatty liver disease [2].

Why Peptide Users Should Track It

Anyone injecting a compounded peptide is introducing a substance that the liver must process. BPC-157 is not FDA-approved, and long-term human safety data do not exist [3]. Tracking AST alongside ALT gives an early signal if liver cells are under stress. This is standard practice for any off-label or investigational compound, not a sign that BPC-157 is presumed dangerous.

How BPC-157 Interacts With Hepatic Tissue

BPC-157 (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a stable pentadecapeptide originally isolated from human gastric juice. Sikiric et al. Have published over 90 papers on its cytoprotective properties across organ systems, including the liver, gut, brain, and musculoskeletal tissue [4].

The Nitric Oxide Pathway

The leading mechanistic hypothesis centers on the nitric oxide (NO) system. BPC-157 appears to modulate NO synthase activity, restoring NO-mediated vasodilation in ischemic tissues and reducing oxidative stress at the cellular level [4]. In hepatocytes specifically, excess reactive oxygen species (ROS) drive mitochondrial membrane permeability, which releases AST into the cytoplasm and then into systemic circulation. By limiting ROS production, BPC-157 may preserve mitochondrial integrity and keep AST inside the cell where it belongs.

The Reticulin Fiber Hypothesis

Separate rodent work from the Zagreb group showed that BPC-157-treated rats maintained reticulin fiber architecture in the liver after partial hepatectomy [5]. Reticulin fibers form the structural scaffolding around hepatocytes. When that scaffolding collapses (as in cirrhosis or acute necrosis), AST and ALT spill into the bloodstream. Maintaining fiber architecture is one plausible route through which BPC-157 could blunt enzyme elevation.

Interaction With the FAK-Paxillin Pathway

A 2018 review by Sikiric et al. Described BPC-157's interaction with focal adhesion kinase (FAK) and paxillin signaling, two proteins involved in cell adhesion and migration [4]. In liver injury models, impaired FAK signaling correlates with poor hepatocyte regeneration and sustained enzyme elevation. BPC-157 appeared to restore FAK-paxillin activation within 24 hours of administration in rats with surgically induced liver lesions, a timeline that aligned with the earliest measurable drops in serum AST.

Preclinical Evidence: AST Outcomes in Animal Models

No human trial has measured BPC-157's effect on AST. All quantitative data come from rodent studies, which limits direct clinical translation. The direction and consistency of results across different injury models is worth examining.

Alcohol-Induced Hepatotoxicity

In a chronic alcohol administration model, rats given BPC-157 (10 mcg/kg intraperitoneally) showed AST levels approximately 45% lower than untreated alcohol-exposed controls after 28 days [5]. ALT followed a similar pattern. Histological scoring confirmed less steatosis and fewer necrotic foci in treated animals.

NSAID-Induced Liver Injury

Nonsteroidal anti-inflammatory drugs can raise liver enzymes at high doses. Sikiric et al. Demonstrated that BPC-157 co-administration with diclofenac in rats attenuated AST elevation by roughly 55% compared to diclofenac-only controls [4]. This finding has practical relevance because many peptide users also take NSAIDs for musculoskeletal complaints.

Ischemia-Reperfusion Injury

When blood supply to the liver is temporarily occluded and then restored, the resulting oxidative burst can destroy hepatocytes and cause a sharp AST spike. Rats pretreated with BPC-157 before hepatic ischemia-reperfusion showed AST values 40-60% lower than saline-treated controls at the 6-hour and 24-hour time points [6]. The protective window appeared to depend on dosing timing: pretreatment was more effective than post-injury administration.

Partial Hepatectomy Recovery

After two-thirds hepatectomy in rats, BPC-157 (10 mcg/kg) accelerated liver mass recovery and reduced peak AST by roughly 50% at 72 hours post-surgery compared to controls [5]. The researchers noted that liver regeneration markers (PCNA-positive hepatocytes) were significantly higher in BPC-157-treated animals, suggesting that faster regeneration limited the duration and peak of enzyme elevation.

The Human Data Gap

Zero published randomized controlled trials have measured AST as a primary or secondary outcome in humans taking BPC-157. This is worth stating plainly. The peptide's legal status complicates formal clinical research.

Regulatory Context

BPC-157 is not an FDA-approved drug. It is available through 503A compounding pharmacies, which operate under state pharmacy board oversight rather than the full FDA new-drug approval pathway [3]. The FDA issued a warning letter in 2022 regarding peptides sold as research chemicals and marketed with therapeutic claims. This regulatory uncertainty has slowed the kind of Phase I/II trials that would generate human hepatic safety data.

Anecdotal Reports

Online peptide communities frequently share bloodwork panels. Some users report stable or declining AST after 4-8 weeks of BPC-157 at doses of 250-500 mcg/day subcutaneously. Others report mild AST elevations of 5-15 IU/L above baseline. These reports lack controls, blinding, and standardized timing relative to meals, exercise, and alcohol, all of which can influence AST by 10-20 IU/L on their own [1]. Self-reported bloodwork cannot substitute for controlled trial data.

What a Proper Trial Would Need

A minimum viable human study would enroll 60-80 participants with normal baseline hepatic panels, randomize them to BPC-157 or placebo, and measure AST, ALT, GGT, and alkaline phosphatase at weeks 0, 2, 4, 8, and 12. Until that study is published, clinicians and patients are working from animal data and first principles.

Practical AST Monitoring Schedule for BPC-157 Users

Even without human trial data, a monitoring framework based on general pharmacovigilance principles is straightforward to implement. The Endocrine Society recommends hepatic panel monitoring for any investigational hormonal or peptide therapy [7].

Baseline Panel

Before the first BPC-157 injection, obtain a comprehensive metabolic panel (CMP) that includes AST, ALT, alkaline phosphatase, total bilirubin, and albumin. Record the values. If baseline AST exceeds 40 IU/L, investigate the cause before starting any peptide.

Week 4 Recheck

At four weeks, repeat AST and ALT. An AST rise of more than 3x the upper limit of normal (above 120 IU/L) warrants immediate discontinuation and hepatology referral. A rise of 1.5-3x ULN (60-120 IU/L) warrants holding the peptide, ruling out confounders (new medications, alcohol, intense exercise within 48 hours of the draw), and rechecking in two weeks [1].

Week 12 Recheck

If the week-4 panel is unremarkable, repeat at 12 weeks. Stable or declining AST at this point provides reasonable (though not definitive) reassurance for continued use. After 12 weeks, every-6-month monitoring is a conservative interval, matching the cadence used for metformin or statin hepatic surveillance in most primary care protocols [8].

Confounders to Control Before Every Blood Draw

Fast for 8-12 hours. Avoid resistance training for 48 hours before the draw. Abstain from alcohol for 72 hours. Document any NSAID or acetaminophen use in the prior week. These steps reduce the noise that makes AST interpretation unreliable. A single elevated AST value without controlling for these variables should not trigger a clinical decision.

AST:ALT Ratio Interpretation on BPC-157

The De Ritis ratio (AST divided by ALT) adds diagnostic context that a standalone AST number cannot provide.

Ratio Below 1.0

This pattern suggests hepatocellular injury of non-alcoholic origin. If both AST and ALT are mildly elevated (40-80 IU/L) with a ratio below 1.0 on BPC-157, the most likely explanation is a mild, non-specific hepatic stress response. Check for other contributing drugs and recheck in two weeks.

Ratio Above 2.0

A ratio above 2.0 is more concerning and historically associated with alcoholic liver disease or advanced fibrosis [2]. If a BPC-157 user shows this pattern, alcohol use should be assessed first. If alcohol is not a factor, muscle-origin AST (from injection-site trauma or concurrent training) could artificially inflate the ratio. Creatine kinase (CK) measurement can help differentiate.

Stable Ratio With Rising Absolute Values

If both AST and ALT climb proportionally and the ratio stays between 0.8 and 1.2, the source is likely hepatic rather than muscular. This pattern on a peptide warrants holding the compound and rechecking in 14 days.

Who Should Be Most Cautious

Not every BPC-157 user carries the same hepatic risk. Certain populations need tighter monitoring or should avoid the peptide entirely until human safety data exist.

Pre-existing Liver Disease

Patients with non-alcoholic fatty liver disease (NAFLD/MASLD), hepatitis B or C, autoimmune hepatitis, or compensated cirrhosis already have elevated baseline enzymes and reduced hepatic reserve. Adding an unstudied peptide to a compromised liver introduces unquantifiable risk [9]. If AST is above 60 IU/L at baseline, BPC-157 should not be started without gastroenterology or hepatology input.

Concurrent Hepatotoxic Medications

Acetaminophen above 2 g/day, methotrexate, amiodarone, valproic acid, and certain azole antifungals all carry hepatotoxic potential. Stacking BPC-157 on top of any of these drugs increases the monitoring burden and the uncertainty around causality if AST rises [8].

Alcohol Use Disorder

Chronic alcohol consumption is the most common cause of AST elevation worldwide [2]. BPC-157's animal-model hepatoprotection occurred in controlled dosing environments, not in the context of ongoing alcohol exposure. A person drinking more than 14 standard drinks per week should address alcohol intake before adding a compounded peptide and tracking AST changes, as the signal-to-noise ratio will be too low to interpret meaningfully.

The Bottom Line on BPC-157 and AST

Animal data show a consistent pattern: BPC-157 reduces elevated AST in multiple hepatic injury models by 40-65%, likely through NO-mediated cytoprotection and preserved hepatocyte architecture. Zero human trials confirm this finding. The responsible approach is to treat BPC-157 as pharmacologically active, monitor AST at baseline, 4 weeks, and 12 weeks, and discontinue if AST exceeds 3x the upper limit of normal. Dr. Predrag Sikiric, the peptide's principal investigator, stated in a 2018 review: "BPC-157 maintains the integrity of the gastrointestinal tract and related organ systems through multiple interacting pathways, including the NO system, prostaglandin system, and dopamine system" [4]. That mechanistic breadth is promising but does not replace the controlled human trials this peptide still lacks. Check your baseline AST before your first injection, not after.